POLE and hepatocellular carcinoma: To challenge this paradigm, we present a patient with hepatocellular carcinoma (HCC) with a rare deleterious POLE mutation outside the exo-domain with a low TMB of 1 mut/Mb and microsatellite stability (MSS) who demonstrated an exceptional response to pembrolizumab.